Tokyo, July 20 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062272) titled 'Effects of Wearing Recovery Wear on SIgA and Heart Rate After Exercise' on July 20.

Study Type: Interventional

Study Design: Basic Design - Cross-over Randomization - Randomized Blinding - Double blind -all involved are blinded Control - Placebo

Primary Sponsor: Institute - EUPHORIA Co., Ltd.

Condition: Condition - Healthy Person Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - To investigate the effects of wearing recovery wear on salivary SIgA after exercise Basic objectives2 - Efficacy

Intervention: Interventions/Control_1 - Recovery Wear Interventions/Control_2 - Placebo

Eligibility: Age-lower limit - 18 years-old <= Age-upper limit - Not applicable Gender - Male and Female Key inclusion criteria - Members of the track and field team.

Individuals who engage in track and field on a regular basis.

Individuals who agree to abide by the prohibitions set forth in this study.

Individuals who consent to the use of study results - in a manner that ensures personal anonymity - for purposes such as academic presentations or corporate advertising.

Individual with the capacity to consent who has received a full explanation of this study, has understood it well, and has voluntarily provided informed consent either online or in writing. Key exclusion criteria - Individuals with serious medical conditions - such as diabetes mellitus, liver disease, kidney disease, heart disease, or cardiovascular disease - or a history thereof.

Individuals currently undergoing treatment for a medical condition, or those with a history of serious illness requiring pharmacological treatment.

Individuals who are not medically cleared for full participation in sports or exercise due to conditions such as heart disease.

Individuals who cannot refrain - during the study period - from the oral intake of new health foods (including supplements affecting the circulatory or metabolic systems), quasi-drugs, or over-the-counter (OTC) medicines, or from the use of topical anti-inflammatory analgesics (such as compresses).However, individuals prescribed such products by a physician or pharmacist for therapeutic purposes must consult them regarding whether to discontinue use; furthermore, if use is unavoidable, it must be carried out with the agreement of the research institution.

Individuals unable to refrain from drinking alcohol or smoking during the study period.

Individuals whose health condition could deteriorate due to wearing the test product (e.g., due to allergies).

Individuals who are pregnant, breastfeeding (including those planning to stop breastfeeding), or intending to become pregnant during the study period.

Individuals who have participated in another clinical study within the past month or plan to participate in another clinical study after consenting to participate in this study.

Any other individuals deemed unsuitable as study participants by their attending physician or the principal investigator Target Size - 24

Recruitment Status: Recruitment status - No longer recruiting Date of protocol fixation - 2024 Year 11 Month 21 Day Date of IRB - 2024 Year 11 Month 21 Day Anticipated trial start date - 2024 Year 11 Month 21 Day Last follow-up date - 2024 Year 12 Month 24 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000071259

Disclaimer: Curated by HT Syndication.